KR101099206B1 - 신규한 글루타미닐 시클라제 저해제 - Google Patents
신규한 글루타미닐 시클라제 저해제 Download PDFInfo
- Publication number
- KR101099206B1 KR101099206B1 KR1020067017874A KR20067017874A KR101099206B1 KR 101099206 B1 KR101099206 B1 KR 101099206B1 KR 1020067017874 A KR1020067017874 A KR 1020067017874A KR 20067017874 A KR20067017874 A KR 20067017874A KR 101099206 B1 KR101099206 B1 KR 101099206B1
- Authority
- KR
- South Korea
- Prior art keywords
- phenyl
- methyl
- group
- compound
- inhibitors
- Prior art date
Links
- HLFFXPADIMAOBA-HKPPKJSDSA-N C/C(/C(CC(CC1)C(C)=C[NH+]1[O-])c(cc1)cc(OC(F)F)c1OC(F)F)=C\C=C(/C)\C(C(F)(F)F)(C(F)(F)F)O Chemical compound C/C(/C(CC(CC1)C(C)=C[NH+]1[O-])c(cc1)cc(OC(F)F)c1OC(F)F)=C\C=C(/C)\C(C(F)(F)F)(C(F)(F)F)O HLFFXPADIMAOBA-HKPPKJSDSA-N 0.000 description 1
- UOOSTQOIBZUZTQ-UHFFFAOYSA-O CC(C)(c1ccc(CNC(C(CCC=N2)=C2OC(C=CC2N)=CC2[NH3+])=O)cc1)O Chemical compound CC(C)(c1ccc(CNC(C(CCC=N2)=C2OC(C=CC2N)=CC2[NH3+])=O)cc1)O UOOSTQOIBZUZTQ-UHFFFAOYSA-O 0.000 description 1
- WAHPCHKYZZEKKV-UHFFFAOYSA-N CC(c(cc1)ccc1OCc1ccc(CN2CCCC2)cc1)=O Chemical compound CC(c(cc1)ccc1OCc1ccc(CN2CCCC2)cc1)=O WAHPCHKYZZEKKV-UHFFFAOYSA-N 0.000 description 1
- 0 CC1[C@@](C)C(C)=C(C)C2C1N=C(C)*2 Chemical compound CC1[C@@](C)C(C)=C(C)C2C1N=C(C)*2 0.000 description 1
- PCFXLLBBTRBJMF-IYPAPVHQSA-N CCCNC([C@@H]([C@@H](C)C(C)C)N)[U] Chemical compound CCCNC([C@@H]([C@@H](C)C(C)C)N)[U] PCFXLLBBTRBJMF-IYPAPVHQSA-N 0.000 description 1
- CFUHKRLMDNFZED-NHCUHLMSSA-N C[C@H]1N(CCCOc(cc2)ccc2-c(cc2)ccc2C(N2CCOCC2)=O)[C@H](C)CC1 Chemical compound C[C@H]1N(CCCOc(cc2)ccc2-c(cc2)ccc2C(N2CCOCC2)=O)[C@H](C)CC1 CFUHKRLMDNFZED-NHCUHLMSSA-N 0.000 description 1
- ZAZBMJPHIFUGQX-UHFFFAOYSA-N Cc1c(C=C)cc[nH]1 Chemical compound Cc1c(C=C)cc[nH]1 ZAZBMJPHIFUGQX-UHFFFAOYSA-N 0.000 description 1
- GCWOLGIKPSMKIH-LYBHJNIJSA-N Clc(cc1)ccc1/C(/c1ncccc1)=C1\CCC(CC2N=CNCC2)CCC1 Chemical compound Clc(cc1)ccc1/C(/c1ncccc1)=C1\CCC(CC2N=CNCC2)CCC1 GCWOLGIKPSMKIH-LYBHJNIJSA-N 0.000 description 1
- AICIWZXBCZBZMU-UHFFFAOYSA-N NCC(N(Cc1c(C2)cccc1)C2C(O)=O)=O Chemical compound NCC(N(Cc1c(C2)cccc1)C2C(O)=O)=O AICIWZXBCZBZMU-UHFFFAOYSA-N 0.000 description 1
- OTBYLNCJHFPRTL-RQJHMYQMSA-N NCC[C@H](C1)[C@H]1c1c[nH]cn1 Chemical compound NCC[C@H](C1)[C@H]1c1c[nH]cn1 OTBYLNCJHFPRTL-RQJHMYQMSA-N 0.000 description 1
- GIAAMKCACACNCN-ALAWOQLPSA-N O=C(C(C1)C1c1ccccc1)N([C@@H](C1)C(N2CCCC2)=O)C2C1CCCC2 Chemical compound O=C(C(C1)C1c1ccccc1)N([C@@H](C1)C(N2CCCC2)=O)C2C1CCCC2 GIAAMKCACACNCN-ALAWOQLPSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Description
실시예 | R | ESI-MS(M+H) | Res.Act.(%) | IC50(μM) | Ki(μM) |
1 | 메틸 | 199.3 | 4.3 | 13 | |
2 | tert-부틸 | 241.4 | 60.7 | 14.7 | |
3 | 벤질 | 275.4 | 60.9 | 5.67 | |
4 | 페닐 | 261.4 | 42.3 | 4.4 | |
5 | 4-(플루오로)-페닐 | 279.35 | 42.0 | 4.73 | |
6 | 4-(클로로)-페닐 | 295.80 | 1.2 | ||
7 | 4-(에틸)-페닐 | 289.41 | 28.7 | 2.78 | |
8 | 4-(트리플루오로메틸)-페닐 | 329.4 | 38.5 | 3.93 | |
9 | 4-(메톡시-카르보닐)-페닐 | 319.4 | 1.19 | ||
10 | 4-(아세틸)-페닐 | 303.4 | 17.0 | 1.70 | |
11 | 4-(메톡시)-페닐 | 291.4 | 9.7 | 0.70 | |
12 | 비시클로[2.2.1]헵트-5-엔-2-일 | 277.5 | 16.0 | ||
13 | 3,4-(디메톡시)-페닐 | 321.5 | 0.7 | 0.22 | 0.06 |
14 | 2,4-(디메톡시)-페닐 | 321.5 | 2.2 | 0.57 | |
15 | 3,5-(디메톡시)-페닐 | 321.5 | 2.86 | 0.75 | |
16 | 2-(메톡시-카르보닐)-페닐 | 319. 4 | |||
17 | 4-(옥사졸-5-이)-페닐 | 328.5 | 3.64 | 0.86 | |
18 | 4-(피라졸-5-이)-페닐 | 327.4 | |||
19 | 4-(이소프로필)-페닐 | 303.5 | 8.7 | ||
20 | 4-(피페리딘-1-술포닐)-페닐 | 408.6 | 8.5 | 2.27 | |
21 | 4-(몰포린-4-일)-페닐 | 346.5 | 9.0 | ||
22 | 4-(시아노)-페닐 | 286.4 | 9.0 | 2.89 | |
23 | 2,3-디히드로-벤조[1,4]디옥신-6-일 | 319.4 | 4.17 | 1.12 | |
24 | 벤조[1,3]디옥솔-5-일 | 305.4 | 16.7 | 5.66 | |
25 | 3,4,5(트리메톡시)-페닐 | 351.5 | 1.7 | 0.34 | |
26 | 3-(메톡시)-페닐 | 291.4 | 6.8 | 1.86 | |
27 | 4-(에톡시)-페닐 | 305.5 | 7.2 | 0.89 | |
28 | 4-(벤질옥시)-페닐 | 367.5 | 0.98 | ||
29 | 4-(메톡시)-벤질 | 305.5 | 3.93 | ||
30 | 3,4-(디메톡시)-벤질 | 335.5 | 1.55 | ||
31 | 2-(메톡시-카르보닐)-티오펜-3-일 | 325. 5 | |||
32 | 3-(에톡시-카르보닐)-4,5,6,7-테트라히드로벤조[b]티오-펜-2-일 | 392. 6 | |||
33 | 2-(메톡시-카르보닐)-4-(메틸)-티오펜-3-일 | 339.5 | |||
34 | 벤조[c][1,2,5]티아졸-4-일 | 319. 5 | |||
35 | 벤조[c][1,2,5]티아졸-5-일 | 319.5 | 4.4 | 1.37 | |
36 | 5-(메틸)-3-(페닐)-이소옥사졸-4-일 | 342.5 | |||
37 | 3,5-(디메틸)-이소옥사졸-4-일 | 280.4 | |||
38 | 4-(이도)-페닐 | 387.3 | 23.5 | 2.12 | |
39 | 4-(브로모)-페닐 | 340.3 | 2.52 | ||
40 | 4-(메틸)-페닐 | 275.4 | 31.3 | 2.14 | |
41 | 나프탈렌-1-일 | 311.5 | 26.7 | 2.79 | |
42 | 4-(니트로)-페닐 | 306.4 | 31.1 | 2.68 | |
43 | 부틸 | 241.4 | 53.8 | 14.0 | |
44 | 시클로옥틸 | 295.5 | 33.1 | 9.1 | |
45 | 퓨란-2-일메틸 | 265.4 | 61.4 | 10.0 | |
46 | 테트라히드로퓨란-2-일메틸 | 269.4 | 46.0 | 12.8 | |
47 | 벤조[1,3]디옥솔-5-일메틸 | 319.4 | 42.7 | 6.1 | |
48 | 2-(몰핀-4-일)-에틸 | 298.5 | 55.0 | 13.3 | |
49 | 4-(메틸술파닐)-페닐 | 307.5 | 19.1 | 1.66 | |
50 | 4-(디메틸아미노)-페닐 | 304.5 | 2.03 | ||
51 | 4-(트리플루오로메톡시)-페닐 | 345.4 | 14.2 | ||
52 | 벤조일 | 288.3 | |||
53 | 피리딘-4-일 | 261.1 |
실시예 | R1 | R2 | ESI-MS(M+H) | Res.Act.(%) | Ki(μM) |
54 | 시아노 | 메틸 | 207.3 | 1.5 | |
55 | 시아노 | 3,4-(데메톡시)-페닐 | 329.4 | 1.36 | |
56 | 시아노 | 2,4-(데메톡시)-페닐 | 329.4 | ||
57 | 시아노 | 3,5-(데메톡시)-페닐 | 329.4 | 0.91 | |
58 | 시아노 | 2,3-디히드로벤조[b][1,4]디옥신-7-일 | 327.4 | 0.64 | |
59 | 시아노 | 벤조[d][1,3]디옥솔-6-일 | 313.4 | 0.73 | |
60 | 시아노 | 3,4,5-(트리메톡시)-페닐 | 359.4 | 0.88 | |
61 | 시아노 | 3-(메톡시)-페닐 | 299.4 | ||
62 | 시아노 | 4-(에톡시)-페닐 | 313.4 | ||
63 | 시아노 | 4-(벤질옥시)-페닐 | 375.5 | ||
64 | 시아노 | 페닐 | 269.4 | 1.02 | |
65 | 시아노 | 4-(메톡시)-페닐 | 299.4 | 0.70 | |
66 | 시아노 | 4-(아세틸)-페닐 | 311.4 | ||
67 | 시아노 | 4-(니트로)-페닐 | 311.4 | ||
68 | 시아노 | 벤질 | 283.4 | 22.5 | 8.17 |
69 | 시아노 | 나프탈렌-1-일 | 319.4 | ||
70 | 시아노 | 4-(플루오로)-페닐 | 387.3 | ||
71 | 시아노 | 4-(이오도)-페닐 | 395.3 | ||
72 | 시아노 | 4-(브로모)-페닐 | 348.3 | ||
73 | 시아노 | 클로로옥틸 | 289.4 | ||
74 | 시아노 | tert-부틸 | 249.3 | ||
75 | 시아노 | 4-(메틸)-페닐 | 283.3 | 1.34 | |
76 | 시아노 | 4-(메틸티오)-페닐 | 315.5 | ||
77 | 시아노 | 4-(에틸)-페닐 | 297.4 | ||
78 | 시아노 | 4-(디메틸아미노)-페닐 | 312.4 | ||
79 | 시아노 | 부틸 | 249.4 | ||
80 | 시아노 | 트리틸 | 435.6 | ||
81 | 시아노 | 벤조[d][1,3]디옥솔-6-일)메틸 | 327.4 | 1.53 | |
82 | 시아노 | (테트라히드로퓨란-2-일)메틸 | 277.4 | ||
83 | 시아노 | 4-(트로플루오로메틸)-페닐 | 334.4 | ||
84 | 시아노 | (퓨란-2-일)메틸 | 273.4 | ||
85 | 시아노 | 2-(몰핀-4-일)-에틸 | 306.4 | ||
86 | 시아노 | 4-(옥사졸-5-일)-페닐 | 336.4 | ||
87 | 시아노 | 피리딘-3-일 | 270.4 | ||
88 | 시아노 | 4-(시아노)-페닐 | 294.4 | ||
89 | 시아노 | 4-(트리플루오로메톡시)-페닐 | 353.4 | ||
90 | 시아노 | 4-(피레리디노술포닐)-페닐 | 416.6 | ||
91 | 시아노 | 4-(1H-피라졸-1-일)-페닐 | 335.4 | ||
92 | H | 3,4-(디메톡시)-페닐 | 304.4 | 204.5 | |
93 | 메틸 | 3,4-(디메톡시)-페닐 | 318.4 | 3.62 | |
94 | 시아노 | 2,3,4-(트리메톡시)-페닐 | 358.1 | ||
95 | 시아노 | 시클로헵틸 | 288.2 | 3 |
실시예 | R | ESI-MS(M+H) | Res.Act.(%) | IC50(μM) | Ki(μM) |
96 | 에틸 | 197.3 | 19.2 | ||
97 | 6-플루오로-4H-벤조[d][1,3]디옥신-8-일 | 321.4 | 19.0 | 12.0 | |
98 | 3-(시클로펜틸옥시)-4-(메톡시)-페닐 | 359.4 | 2.87 | 0.62 | |
99 | 4-(헵틸옥시)-페닐 | 359.5 | 5.6 | 9.9 | |
100 | 3,4-디히드로-2H-벤조[b][1,4]디옥세핀-7-일 | 317.4 | |||
101 | 4-(부톡시)-페닐 | 371.4 | |||
102 | 3,4-(디메톡시)-페닐 | 305.4 | 0.46 |
실시예 | 벤질-치환의 위치 | ESI-MS(M+H) | Res.Act.(%) | Ki(μM) |
103 | 2 | 383.5 | 16.27 | 4.84 |
104 | 3 | 383.5 | 3.52 | |
105 | 4 | 383.5 | 1.86 |
실시예 | R4 | R5 | ESI-MS(M+H) | Res.Act.(%) | IC50(μM) | Ki(μM) |
106(S) | H | 메틸 | 335.5 | 0.76 | ||
107(R) | 메틸 | H | 335.5 | 0.35 | ||
108 | 메틸 | 메틸 | 349.5 | |||
109 | -CH2-CH2- | 347.5 | 7.85 |
실시예 | R6 | ESI-MS(M+H) | Res.Act.(%) | IC50(μM) | Ki(μM) |
110 | H | 259.4 | 3.00 | ||
111 | 클로로 | 293.8 | 3.35 | ||
112 | 메톡시 | 289.4 | 1.57 |
실시예 | R7 | R8 | R9 | ESI-MS (M+H) |
Res.Act. (%) |
Ki(μM) |
113 | 페닐 | H | H | 260.4 | 4.62 | |
114 | 티오펜-2-일 | H | H | 266.5 | 3.29 | |
115(R) | 페닐 | 메틸 | H | 274.5 | 21.2 | 7.34 |
116(S) | 페닐 | H | 메틸 | 274.5 | 8.1 | 3.51 |
117 | 페닐 | H | 에틸 | 288.5 | 3.57 | |
118 | 페닐 | H | 페닐 | 336.5 | 13.5 | 4.48 |
119 | 3,4-(디메톡시)-페닐 | H | H | 320.5 | 0.39 | |
120 | 3,4-(디메톡시)-페닐 | 메틸 | 메틸 | 347.2 | ||
121 | 4-(클로로)-페닐 | -CH2-CH2-CH2- | 334.9 | 4.88 | ||
122 | 4-(클로로)-페닐 | -CH2-C2H4-CH2- | 349.0 | 7.3 | ||
123 | 4-(메톡시)-페닐 | -CH2-C3H6-CH2- | 358.6 | 2.78 | ||
124 | 4-(메톡시)-페닐 | -CH2-CH2- | 316.5 | 0.39 | ||
125 | 3,4-(디메톡시)-페닐 | -CH2-CH2- | 346.5 | 0.09 | ||
126 | 3,4,5-(트리메톡시)-페닐 | -CH2-CH2- | 376.6 | |||
127 | 2,3,4-(트리메톡시)-페닐 | -CH2-CH2- | 376.6 | |||
128 | 2-(메톡시)-페닐 | -CH2-CH2- | 316.5 | |||
129 | 3-(메톡시)-페닐 | -CH2-CH2- | 316.5 | |||
130 | 2,3-(디메톡시)-페닐 | -CH2-CH2- | 346.5 | |||
131 | 3,5-(디메톡시)-페닐 | -CH2-CH2- | 346.5 | |||
132 | 2,5-(디메톡시)-페닐 | -CH2-CH2- | 346.5 |
실시예 | N | ESI-MS(M+H) | Ki(μM) |
133 | 3 | 306.5 | |
134 | 4 | 320.5 | 0.99 |
135 | 5 | 334.5 |
실시예 | m | ESI-MS(M+H) | Res.Act.(%) | Ki(μM) |
136 | 2 | 307.4 | 17.6 | |
137 | 4 | 335.5 | 2.19 | 0.55 |
펩티드 | 아미노산 서열 | 기능 |
가스트린 17 Swiss-Prot: P01350 |
QGPWL EEEEEAYGWM DF (아미드) | 가스트린(gastrin)은 위점막에서 염산의 생성 및 분비와 췌장에서 소화효소의 분비를 촉진한다. 또한, 평활근 수축을 촉진하고 위장에서 혈액순환 및 물 분비를 증가시킨다. |
뉴로텐신 Swiss-Prot: P30990 |
QLYENKPRRP YIL | 뉴로텐신은 지방대사 조절에 있어서내분비 또는 측분비(paracrine) 역할을 수행한다. 평활근의 수축을 유발한다. |
FPP | QEP 아미드 | 갑상선자극호르몬 방출 호르몬(thyrotrophin releasing hormone(TRH))과 관련된 트리펩티드는 정장에서 발견된다. 생체외 및 생체내에서 수득한 최근의 증거에 따르면 FPP는 정자수정능력의 조절에 있어서 중요한 역할을 수행하는 것으로 밝혀졌다. |
TRH Swiss-Prot: P20396 |
QHP 아미드 | TRH는 뇌하수체 전엽에서 TSH 생합성의 조절자로서 중추 및 말초 신경계에서는 신경전달물질/신경조절물질로서 작용한다. |
GnRH Swiss-Prot: P01148 |
QHWSYGL RP(G) 아미드 | 생식선자극호르몬(gonadotropin)의 분비촉진; 황체형성호르몬 및 난포자극호르몬의 분비촉진 |
CCL16(작은 유도성 사이토카인 A16) Swiss-Prot: O15467 |
QPKVPEW VNTPSTCCLK YYEKVLPRRL WGYRKALNC HLPAIIFVTK RNREVCTNPN DDWVQEYIKD PNLPLLPTRN LSTVKIITAK NGQPQLLNSQ |
림프구와 단핵구에 대해 주화활성(chemotactic activity)을 나타내나 중성구에는 주화능을 나타내지 않는다. 또한, 강력한 골수억제활성을 나타내고, 골수전구세포의 증식을 억제한다. 재조합 SCYA16은 단핵구와 THP-1 단핵구에 대해 주화활성을 나타내나 휴지기 림프구 및 중성구에 대해서는 주화활성을 나타내지 않는다. RANTES 발현에 의해 탈감작된 THP-1에서 칼슘유출을 유발한다. |
CCL8(작은 유도성 사이토카인 A8) Swiss-Prot: P80075 |
QPDSVSI PITCCFNVIN RKIPIQRLES YTRITNIQCP KEAVIFKTKR GKEVCADPKE RWVRDSMKHL DQIFQNLKP |
단핵구, 림프구, 호염구 및 호산구를 끌어들이는 주화인자임. 종양(neoplasia) 및 염증성 숙주반응에 관여한다. 이 단백질은 헤파린에 결합할 수 있다. |
펩티드 | 아미노산 서열 | 기능 |
CCL2(작은 유도성 사이토카인 A2) Swiss-Prot: P13500 |
QPDAINA PVTCCYNFTN RKISVQRLAS YRRITSSKCP KEAVIFKTIV AKEICADPKQ KWVQDSMDHL DKQTQTPKT |
중성구 또는 호산구를 끌어들이지는 못하나 단핵구와 호염구를 끌어들이는 주화인자임. 단핵구 항암활성을 증강시킴. 건선, 류마티스관절염 또는 동맥경화증과 같은 단핵구의 침윤을 특징으로 하는 질환의 병인에 관련되어 있음. 동맥경화증의 진행과정 동안에 단핵구의 동맥벽 내로의 이동에 관여함. CCR2 및 CCR4에 결함함. |
CCL18(작은 유도성 사이토카인 A18) Swiss-Prot: P55774 |
QVGTNKELC CLVYTSWQIP QKFIVDYSET SPQCPKPGVI LLTKRGRQIC ADPNKKWVQK YISDLKLNA |
단핵구 또는 과립구를 끌어들이지는 못하나 림프구를 끌어들이는 주화인자임. 림프절에서 B 세포의 B 세포 림프소절 내로의 이동에 관여함. 림프절에서 한번도 항원에 노출되지 않은(naive) T 림프구를 수지상세포 및 활성화된 대식세포로 끌어들이고, naive T 세포, CD4+ 및 CD8+ T 세포에 대해 주화활성을 가지며, 따라서 체액성 및 세포매개 면역반응 모두에 관여함. |
프락탈킨(뉴로탁틴(neurotactin)) Swiss-Prot: P78423 |
QHHGVT KCNITCSKMT SKIPVALLIH YQQNQASCGK RAIILETRQH RLFCADPKEQ WVKDAMQHLD RQAAALTRNG GTFEKQIGEV KPRTTPAAGG MDESWLEPE ATGESSSLEP TPSSQEAQRA LGTSPELPTG VTGSSGTRLP PTPKAQDGGP VGTELFRVPP VSTAATWQSS APHQPGPSLW AEAKTSEAPS TQDPSTQAST ASSPAPEENA PSEGQRVWGQ GQSPRPENSL EREEMGPVPA HTDAFQDWGP GSMAHVSWP VSSEGTPSRE PVASGSWTPK AEEPIHATMD PQRLGVLITP VPDAQAATRR QAVGLLAFLG LLFCLGVAMF TYQSLQGCPR KMAGEMAEGL RYIPRSCGSN SYVLVPV |
가용성 형태는 T 세포와 단핵구에 ㄷ대해 주화능을 가지나 중성구에 대해서는 주화능을 가지지 않는다. 막결합형은 내피세포에 백혈구의 부착을 촉진한다. 내피에서 백혈구 부착 및 이동의 조절에 관여한다. CX3CR1에 결합한다. |
CCL7(작은 유도성 사이토카인 A7) Swiss-Prot: P80098 |
QPVGINT STTCCYRFIN KKIPKQRLES YRRTTSSHCP REAVIFKTKL DKEICADPTQ KWVQDFMKHL DKKTQTPKL |
중성구를 끌어들이지는 못하나 단핵구와 호산구를 끌어들이는 주화인자임. 단핵구 항암활성을 증강시킴. 겔라티나제 B(gelatinase B)의 방출을 유도함. 이 단백질은 헤파린에 결합할 수 있음. CCR1, CCR2 및 CCR3에 결합함. |
펩티드 | 아미노산 서열 | 기능 |
오렉신 A (히포크레틴-1(hypocretin-1)) Swiss-Prot: 043612 |
QPLPDCCRQK TCSCRLYELL HGAGNHAAGI LTL |
음식섭취 및 수면-각성의 조절에서 중요한 역할을 담당하는 신경펩티드로서 가능하게는 이러한 보완적 항상성 기능의 복잡한 행동적 및 생리적 응답을 통합함으로써 작용한다. 또한, 에너지대사의 항상성 조절, 자율기능, 호르몬 균형 및 체액조절에서 광범위한 역할을 수행한다. 오렉신-A는 높은 친화력으로 OX1R 및 OX2R 모두에 결합한다. |
기질 P (substance P) |
RPK PQQFFGLM | 타키키닌(tachykinin)군에 속함. 타키키닌은 뉴런을 흥분시키는 활성 펩티드로서 행동적 응답을 일으키고, 강력한 혈관확장제 및 분비촉진제이고, 많은 평활근을 (직접 또는 간접적으로) 수축시킨다. |
회사 | 약물 코드 | 구조 |
Celgene Corp | CC-002 | |
Celltech Group plc/ Merck Frosst | L-826141 | |
Celltech Group plc | Sch-351591 (D- 4396) | |
Dainippon Pharmaceutical Co Ltd | OS-0217 | |
IBFB Pharma GmbH | IBFB-130011 IBFB-150007 IBFB-130020 IBFB-140301 |
|
ICOS Corp | IC-485 | |
Kings College London | VMX-554 VMX-565 |
|
Memory Pharmaceuticals Corp | MEM-1414 MEM-1018 MEM-1091 MEM-1145 |
회사 | 약물코드 | 구조 |
Pfizer Inc | CI-1044 | |
Pfizer Inc | BHN | |
Schering AG | ZK-117137 | |
SmithKline Beecham Pharmaceuticals | SB-207499 유사체, GSK |
회사 | 약물 | 구조 |
Abbott 실험실 |
A-331440 | |
Abbott 실험실 | A-349821 | |
Aventis Pharma AG |
3874-H1 | |
베를린 자유대학 | UCL-2173 | |
BioProjet, Societe Civile de Recherche |
회사 | 약물 | 구조 |
BioProjet, Societe Civile de Recherche | UCL-1470 | |
대웅제약주식회사 | DWP-302 | |
GlaxoSmithKline Inc | GSK-189254A GSK-207040A |
|
Gliatech Inc | 시프라리산트(cipralisant) | |
Gliatech Inc | GT-2203 | |
호카이도대학 | 1S,2S)-2-(2-아미노에틸)-1-(1H-이미다졸-4-일)시클로프로판 | |
Johnson & Johnson | JNJ-5207852 | |
Novo Nordisk A/S | NNC-0038-O0000-1049 |
회사 | 약물 | 구조 |
Schering-Plough Research Institute | dual H1/H3 길항제 | |
Schering-Plough Research Institute | Sch-79687 |
Z-321 | ONO -1603 |
Zeria 제약회사 | Ono 제약회사 |
(4R)-3-(인단-2-일아세틸)-4-(1-피롤리디닐-카르보닐)-1,3-티아졸이딘 | (S)-1-[N-(4-클로로벤질)-숙신아모일] ㅍ피롤리딘-2-카르브알데히드 |
JTP-4819 | S-17092 |
일본 담배회사 | Servier |
(S)-2-{[(S)(히드록시아세틸)-1-피롤리디닐] 카르보닐}-N-(페닐메틸)-1-피롤리딘- 카르복사미드 | (2S, 3aS, 7aS)-1 { [ (R, R)-2-페닐시클로프로필]-카르닐}-2-[(티아졸리딘-3-일) 카르보닐] 옥타히드로-1H-인돌 |
회사 | 약물 코드 | 구조 |
Bristol-Myers Squibb Co | BMS-477118 | |
Eisai Co Ltd | ||
Ferring Research Ltd | FE-999011 | |
GIaxoSmithKline plc | GW-229A | |
Kyowa Hakko Kogyo | K-579 | |
Merck & Co Inc | MK-431 |
회사 | 약물코드 | 구조 |
Novartis AG | LAF-237 | |
Novo Nordisk A/S | ||
Novo Nordisk A/S | 발린 피롤리딘 | |
Pfizer Inc | CP-867534-01 | |
Phenomix Corp. | PHX-1004 | |
Point Therapeutics Inc. | PT-100 (Talabostat) | |
Sanofi-Synthelabo | SSR-162369 | |
Syrrx Inc | SYR-322 | |
Taisho Pharmaceutical Co Ltd |
회사 | 약물코드 | 구조 |
Tanabe Seiyaku Co Ltd | TSL-225 | |
Tanabe Seiyaku Co Ltd (GlaxoSmithKline plc로 인가됨) |
815541 (T-6666) |
DP IV 저해제 |
H-Asn-피롤리딘 |
H-Asn-티아졸리딘 |
H-Asp-피롤리딘 |
H-Asp-티아졸리딘 |
H-Asp(NHOH)-피롤리딘 |
H-Asp(NHOH)-티아졸리딘 |
H-Glu-피롤리돈 |
H-Glu-티아졸리딘 |
H-Glu(NHOH)-피롤리딘 |
H-Glu(NHOH)-티아졸리딘 |
H-His-피롤리돈 |
H-His-티아졸리딘 |
H-Pro-피롤리돈 |
H-Pro-티아졸리딘 |
H-Ile-아지디딘 |
H-Ile-피롤리돈 |
H-L-allo-Ile-티아졸리딘 |
H-Val-피롤리돈 |
H-Val-티아졸리돈 |
펩티드 | 질량(계산치) | 질량(실험치)1 [M+H+] |
2-아미노 옥탄산-Pro-Ile | 369.5 | 370.2 |
Abu-Pro-Ile | 313.4 | 314.0 |
Aib-Pro-lle | 313.4 | 314.0 |
Aze-Pro-Ile | 311.4 | 312.4 |
Cha-Pro-lle | 381.52 | 382.0 |
Ile-Hyp-Ile | 356.45 | 358.2 |
Ile-Pro-allo-Ile | 341.4 | 342.0 |
Ile-Pro-t-부틸-Gly | 341.47 | 342.36 |
Ile-Pro-Val | 327.43 | 328.5 |
Nle-Pro-lle | 341.45 | 342.2 |
Nva-Pro-Ile | 327.43 | 328.2 |
Orn-Pro-lle | 342.42 | 343.1 |
Phe-Pro-Ile | 375.47 | 376.2 |
Phg-Pro-Ile | 361.44 | 362.2 |
Pip-Pro-Ile | 338.56 | 340.0 |
Ser(Bzl)-Pro-Ile | 405.49 | 406.0 |
Ser(P)-Pro-Ile | 395.37 | 396.0 |
Ser-Pro-Ile | 315.37 | 316.3 |
t-부틸-Gly-Pro-D-Val | 327.4 | 328.6 |
t-부틸q-Gly-Pro-Gly | 285.4 | 286.3 |
t-부틸-Gly-Pro-Ile | 341.47 | 342.1 |
t-부틸-Pro-Ile-amide | 340.47 | 341.3 |
t-부틸-Gly-Pro-t-butyl-Gly | 341.24 | 342.5 |
t-부틸-Gly-Pro-Val | 327.4 | 328.4 |
Thr-Pro-Ile | 329.4 | 330.0 |
Tic-Pro-Ile | 387.46 | 388.0 |
Trp-Pro-Ile | 414.51 | 415.2 |
Tyr(P)-Pro-Ile | 471.47 | 472.3 |
Tyr-Pro-allo-Ile | 391.5 | 392.0 |
Val-Pro-allo-Ile | 327.4 | 328.5 |
Val-Pro-t-부틸-Gly | 327.4 | 328.15 |
Val-Pro-Val | 313.4 | 314.0 |
Claims (57)
- 약제학적으로 허용가능한 염의 형태를 포함하는 하기 화학식 1의 화합물:화학식 1여기서,A는 비분지형 C3 알킬 사슬이고; 및B는 하기의 (VI) 또는 (VII)로부터 선택된 기(group)이다:여기서,B가 (VI)기인 경우,D는 디히드로벤조디옥신, 벤조디옥솔, 벤조디티올 디히드로벤조디티인, 벤조옥사티올 또는 디히드로벤조옥사티인이거나; 또는 D는 터트-부틸, 벤질, 페닐, 4-플루오로-페닐, 4-클로로-페닐, 4-에틸-페닐, 4-(트리플루오로메틸)-페닐, 4-(메톡시카르보닐)-페닐, 4-(아세틸)-페닐, 4-(메톡시)-페닐, 바이사이클로[2.2.1]헵트-5-엔-2-일, 3,4-(디메톡시)-페닐, 2,4-(디메톡시)-페닐, 3,5-(디메톡시)-페닐, 2-(메톡시카르보닐)-페닐, 4-(옥사졸-5-일)-페닐, 4-(피라졸-1-일)-페닐, 4-이소프로필-페닐, 4-(피페리딘-1-설포닐)-페닐, 4-(몰폴린-4-일)-페닐, 4-시아노-페닐 2,3-디하이드로-벤조[1,4]-디옥신-6-일, 벤조[1,3]디옥솔-5-일, 3,4,5-(트리메톡시)-페닐, 3-(메톡시)-페닐, 4-(에톡시)-페닐, 4-(벤질옥시)-페닐, 4-아이오도-페닐, 4-브로모-페닐, 4-메틸-페닐, 나프탈렌-1-일, 4-니트로-페닐, 사이클로옥틸, 퓨란-2-일-메틸, 테트라하이드로퓨란-2-일-메틸, 벤조[1,3]디옥솔-5-일메틸, 2-(몰폴린-4-일)-에틸, 4-(메틸설파닐)-페닐, 4-(디메틸아미노)-페닐, 4-(트리플루오로메톡시)-페닐, 벤조일 또는 피리딘-4-일이고; 또는B가 (VII)기인 경우,D는 치환된 페닐를 나타내고, 여기서 치환은 C1-12 알콕시-, -티오알킬, 할로겐, 또는 카르복시산 알킬 또는 C6-12 아릴 에스터를 의미하고; 또는 D는 디히드로벤조디옥신, 벤조디옥솔, 벤조디티올 디히드로벤조디티인, 벤조옥사티올 또는 디히드로벤조옥사티인을 나타내고; 또는B가 (VII)기이고 R17 및 R18이 모두 수소인 경우, D는 추가적으로 페닐이고;X는 S를 나타내고;Y는 S이고;R17 및 R18은 모두 H이거나; R17과 R18중 하나는 H이고 다른 하나는 메틸이고; 또는 R17과 R18은 연결되어 최대 6개의 고리원자를 가지는 탄소고리를 형성할 수 있으며;및여기서 상기 용어 알킬은 메틸, 에틸, 프로필 또는 부틸을 의미하고;또는 약제학적으로 허용가능한 염의 형태를 포함하는 하기 화학식 1b의 화합물:화학식 1b여기서 상기 R2는,비치환 페닐, 또는 에톡시, 벤질옥시, 메톡시, 아세틸, 니트로, 할로, 메틸, 에틸, 메틸티오, 디메틸아미노 또는 트리플루오로메틸로부터 선택되는 치환기로 4번 위치에 치환된 페닐;3-메톡시페닐, 3,4-디메톡시페닐, 2,4-디메톡시페닐, 3,5-디메톡시페닐 또는 3,4,5-트리메톡시페닐; 또는메틸, 2,3-디하이드로벤조[b][1,4]디옥신-7-일, 벤조[d][1,3]디옥솔-6-일, 벤질, 나프탈레닐, 사이클로옥틸, 터트-부틸, 부틸, 트리틸, 벤조[d][1,3]디옥솔-6-일메틸, (테트라하이드로퓨란-2-일)메틸, (퓨란-2-일)메틸 또는 2-(몰폴린-4-일)에틸이다.
- 제1항에 있어서, B는 (VI)기(group)인 화합물.
- 삭제
- 제1항에 있어서, B는 (VII)기(group)인 화합물.
- 삭제
- 제4항에 있어서, R17 및 R18이 모두 H인 화합물.
- 제4항에 있어서, R17과 R18중 하나는 H이고 다른 하나는 메틸인 화합물.
- 제4항에 있어서, R17과 R18은 연결되어 최대 6개의 고리원자를 가지는 탄소고리를 형성하는 화합물.
- 약제학적으로 허용가능한 염의 형태를 포함하는 하기 화학식 1a의 화합물:화학식 1a여기서, R기는 tert-부틸, 벤질, 페닐, 4-플루오로-페닐, 4-클로로-페닐, 4-에틸-페닐, 4-(트리플루오로메틸)-페닐, 4-(메톡시카르보닐)-페닐, 4-(메틸시카르보닐)-페닐, 4-(메톡시)-페닐, 비시클로[2.2.1]헵트-5-엔-2-일, 3,4-(디메톡시)-페닐, 2,4-(디메톡시)-페닐, 3,5-(디메톡시)-페닐, 2-(메톡시카르보닐)-페닐, 4-(옥사졸-5-일)-페닐, 4-(피라졸-1-일)-페닐, 4-이소프로필-페닐, 4-(피페리딘-1-술포닐)-페닐, 4-(몰포린-4-일)-페닐, 4-시아노-페닐 2,3-디히드로-벤조[1,4]-디옥신-6-일, 벤조[1,3]-디옥솔-5-일, 3,4,5-(트리메톡시)-페닐, 3-(메톡시)-페닐, 4-(에톡시)-페닐, 4-(벤질옥시)-페닐, 4-아이오도-페닐, 4-브로모-페닐, 4-메틸-페닐, 나프탈렌-1-일, 4-니트로-페닐, 시클로옥틸, 퓨란-2-일-메틸, 테트라히드로퓨란-2-일-메틸, 벤조[1,3]-디옥솔-5-일-메틸, 2-(몰포린-4-일)에틸, 4-(메틸술파닐)-페닐, 4-(디메틸아미노)-페닐, 4-(트리플루오로메톡시)-페닐, 벤조일 또는 피리딘-4-일을 나타낸다.
- 제9항에 있어서, 상기 R기가 3,4-(디메톡시)-페닐을 나타내는 화학식 1a의 화합물.
- 약제학적으로 허용가능한 염의 형태를 포함하는 하기 화학식 1b의 화합물:화학식 1b여기서, R2기는 메틸, tert-부틸, 벤질, 페닐, 4-플루오로-페닐, 4-에틸-페닐, 4-(트리플루오로메틸)-페닐, 4-(메톡시카르보닐)-페닐, 4-(메틸시카르보닐)-페닐, 4-(메톡시)-페닐, 3,4-(디메톡시)-페닐, 2,4-(디메톡시)-페닐, 3,3,4-(트리메톡시)-페닐, 3,5-(디메톡시)-페닐, 2,3-디히드로-벤조[1,4]-디옥신-6-일, 벤조[d][1,3]-디옥솔-6-일, 3-(메톡시)-페닐, 4-(에톡시)-페닐, 4-(벤질옥시)-페닐, 4-아이오도-페닐, 4-브로모-페닐, 4-메틸-페닐, 나프탈렌-1-일, 4-니트로-페닐, n-부틸, 시클로옥틸, 퓨란-2-일-메틸, 테트라히드로퓨란-2-일-메틸, 벤조[d][1,3]-디옥솔-6-일-메틸, 2-(몰포린-4-일)에틸, 4-(디메틸아미노)-페닐, 4-(메틸술파닐)-페닐, 또는 트리틸을 나타낸다.
- 삭제
- 약제학적으로 허용가능한 염의 형태를 포함하는 하기 화학식 1g의 화합물:화학식 1g여기서, R7기는 페닐 또는 3,4-(디메톡시)-페닐을 나타내고, R8기 및 R9기는 모두 H이거나;R7기는 페닐이고, R8과 R9 중 하나는 H이고 다른 하나는 메틸이거나;R7기는 4-(클로로)-페닐을 나타내고, R8기 및 R9기는 이들이 부착된 탄소원자와 함께 시클로부틸 또는 시클로펜틸 고리를 형성하거나; 또는R7기는 4-(메톡시)-페닐을 나타내고, R8기 및 R9기는 이들이 부착된 탄소원자와 함께 시클로프로필 또는 시클로헥실 고리를 형성한다.
- 삭제
- 제13항에 있어서, 상기 R7기는 3,4-(디메톡시)-페닐을 나타내고, 상기 R8기 및 R9기는 모두 H인 화학식 1g의 화합물.
- 제13항에 있어서, 상기 R8기 및 R9기는 이들이 부착된 탄소원자와 함께 시클로프로필 고리를 형성하고, 상기 R7기는 3,4-(디메톡시)-페닐을 나타내는 화학식 1g의 화합물.
- 제1항, 제2항, 제4항, 제6항 내지 제11항, 제13항 및 제15항 내지 제17항 중 어느 한 항에 있어서, 약물로서 사용되는 화합물.
- 선택적으로 치료학적으로 허용가능한 담체 또는 부형제와 조합되게 제1항, 제2항, 제4항, 제6항 내지 제11항, 제13항 및 제15항 내지 제17항 중 어느 한 항에 따른 적어도 하나의 화합물을 포함하는, 알츠하이머병, 다운증후군, 파킨스병, 헌팅톤 무도병, 정신병성 병태, 정신분열증, 음식섭취장애, 수면-각성 장애, 에너지 대사의 항상성 조절장애, 자율기능장애, 호르몬균형장애, 체액조절장애, 고혈압, 발열, 수면조절장애, 식욕감퇴, 우울증을 포함하는 불안관련질환, 간질을 포함하는 발작, 약물금단증상 및 알코올중독, 인식기능장애 및 치매를 포함하는 퇴행성 신경질환으로 구성되는 군으로부터 선택되는 신경질환의 치료용 약학적 조성물.
- 제19항에 있어서, 비경구, 경장(enteral) 또는 경구 투여용 약학적 조성물.
- 제19항에 있어서, 프로릴엔도펩티다제(prolylendopeptidase; PEP)-저해제, LiCl, 디펩티딜 아미노펩티다제 저해제, 뉴로펩타이드 Y(neuropeptide Y; NPY)-수용체 리간드, 뉴로펩타이드 Y(neuropeptide Y; NPY) 효현제, 아세틸콜린에스터라제(acetylcholinesterase; ACE)의 저해제, 프로테인 이소아스파르테이트 카르복시메틸 트랜스퍼라제(protein isoaspartate carboxymethyl transferase; PIMT) 증강제, 베타 분비효소(beta secretase)의 저해제, 감마 분비효소의 저해제, 중성 엔도펩티다제의 저해제, 포스포디에스터라제(phosphodiesterase; PDE)-4의 저해제, 모노아민 옥시다제(monoamine oxidase; MAO) 저해제, 투머 네크로시스 팩터 알파(tumor necrosis factor-alpha; TNF-α) 저해제, 아밀로이드 단백질 또는 아밀로이드 펩티드 침착 저해제, 시그마-1 수용체 저해제 및 히스타민 H3 길항제로 이루어진 그룹으로부터 선택되는 적어도 하나의 화합물을 추가적으로 포함하는 약학적 조성물.
- 제21항에 있어서, 상기 뉴로펩타이드 Y(neuropeptide Y; NPY) 길항제가 3a,4,5,9b-테트라히드로-1h-벤즈[e]인돌-2-일 아민, 및 (R)-N2-(디페닐아세틸)-(R)-N-[1-(4-히드록시-페닐)에틸]아르기닌 아미드로 이루어진 그룹으로부터 선택되는 약학적 조성물.
- 제21항에 있어서, 상기 프로릴엔도펩티다제(prolylendopeptidase; PEP) 저해제가 벤질옥시카르보닐-프로릴-프로리날, L-말단 치환된 L-프롤린 또는 L-프로릴피롤리돈, C-말단에 프로리날(prolinal)을 함유하는 치환된 N-벤질옥시카르보닐 (Z) 디펩티드, 치환된 티오프롤린, 치환된 티아졸리딘, 치환된 옥소피롤리돈, 플루오르화된 케톤 유도체, 아실-프롤린 또는 아실펩티드-프롤린(Z-Gly-Pro-CH2Cl)의 클로로메틸 케톤 유도체를 포함하는 C-말단 변형된 프롤린, 및 2-아실피롤리딘 유도체로 이루어진 그룹으로부터 선택되는 약학적 조성물.
- 제21항에 있어서, 상기 아세틸콜린에스터라제(acetylcholinesterase; ACE) 저해제가 리바스티그민(+)-(S)-N-에틸-3-[(1-디메틸아미노)에틸]-N-메틸페닐카르바메이트 히드로겐(수소) 타르타레이트인 약학적 조성물.
- 삭제
- 삭제
- 삭제
- 삭제
- 제19항에 있어서, 상기 신경질환은 알츠하이머병, 다운증후군, 파킨스병 및 헌팅톤 무도병으로 이루어진 그룹으로부터 선택되는 신경질환인 약학적 조성물.
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54213304P | 2004-02-05 | 2004-02-05 | |
US60/542,133 | 2004-02-05 | ||
US10/838,993 | 2004-05-05 | ||
US10/838,993 US7371871B2 (en) | 2003-05-05 | 2004-05-05 | Inhibitors of glutaminyl cyclase |
US63436404P | 2004-12-08 | 2004-12-08 | |
US60/634,364 | 2004-12-08 | ||
PCT/EP2005/001153 WO2005075436A2 (en) | 2004-02-05 | 2005-02-04 | Novel inhibitors of glutaminyl cyclase |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20060125884A KR20060125884A (ko) | 2006-12-06 |
KR101099206B1 true KR101099206B1 (ko) | 2011-12-27 |
Family
ID=40253652
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020067017874A KR101099206B1 (ko) | 2004-02-05 | 2005-02-04 | 신규한 글루타미닐 시클라제 저해제 |
Country Status (9)
Country | Link |
---|---|
US (2) | US7304086B2 (ko) |
EP (1) | EP1713780B1 (ko) |
JP (1) | JP4996926B2 (ko) |
KR (1) | KR101099206B1 (ko) |
CN (1) | CN1918131B (ko) |
AU (1) | AU2005210004B2 (ko) |
BR (1) | BRPI0507485A (ko) |
CA (1) | CA2554809C (ko) |
WO (1) | WO2005075436A2 (ko) |
Families Citing this family (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2328498C9 (ru) * | 2002-12-04 | 2008-12-10 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Соединения с конденсированным 1,3-дигидроимидазольным циклом |
KR20050122220A (ko) | 2003-03-25 | 2005-12-28 | 다케다 샌디에고, 인코포레이티드 | 디펩티딜 펩티다제 억제제 |
DE602004026289D1 (de) * | 2003-05-05 | 2010-05-12 | Probiodrug Ag | Glutaminylcyclase-hemmer |
US8338120B2 (en) | 2003-05-05 | 2012-12-25 | Probiodrug Ag | Method of treating inflammation with glutaminyl cyclase inhibitors |
US7732162B2 (en) * | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
KR20120035203A (ko) * | 2003-05-05 | 2012-04-13 | 프로비오드룩 아게 | 글루타미닐 및 글루타메이트 사이클라제의 이펙터의 용도 |
CN1867560A (zh) | 2003-08-13 | 2006-11-22 | 武田药品工株式会社 | 4-嘧啶酮衍生物及其作为肽基肽酶抑制剂的用途 |
JP2007505121A (ja) | 2003-09-08 | 2007-03-08 | 武田薬品工業株式会社 | ジペプチジルぺプチダーゼ阻害剤 |
US20100099721A1 (en) * | 2003-11-03 | 2010-04-22 | Probiodrug Ag | Novel compounds for the treatment of neurological disorders |
WO2006058720A2 (en) * | 2003-11-03 | 2006-06-08 | Probiodrug Ag | Novel compounds for the treatment of neurological disorders |
US20050171112A1 (en) * | 2003-11-03 | 2005-08-04 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
US7667044B2 (en) | 2003-11-03 | 2010-02-23 | Probiodrug Ag | Compounds for the treatment of neurological disorders |
AU2005210004B2 (en) | 2004-02-05 | 2010-10-28 | Probiodrug Ag | Novel inhibitors of glutaminyl cyclase |
CN102134231B (zh) * | 2004-03-15 | 2020-08-04 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
JP2008524331A (ja) | 2004-12-21 | 2008-07-10 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼ阻害剤 |
KR100650278B1 (ko) * | 2004-12-27 | 2006-11-27 | 김성진 | 엔-아릴 엔' 모르폴리노/ 피페리디노 티오카르바마이드유도체를 유효성분으로 함유하는 당뇨병, 당뇨병 합병증,인슐린저항성 및 그로 인한 인슐린 저항성 증후군의 예방및 치료용 약학적 조성물 |
JP4568361B2 (ja) | 2005-04-22 | 2010-10-27 | アラントス・ファーマシューティカルズ・ホールディング・インコーポレーテッド | ジペプチジルペプチダーゼ−iv阻害剤 |
EA015169B1 (ru) | 2005-09-14 | 2011-06-30 | Такеда Фармасьютикал Компани Лимитед | Применение ингибиторов дипептидилпептидазы |
CA2622642C (en) | 2005-09-16 | 2013-12-31 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US8324383B2 (en) * | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
ATE522216T1 (de) * | 2006-09-13 | 2011-09-15 | Takeda Pharmaceutical | Verwendung von 2-6-(3-amin-piperidin-1-yl)-3- methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1- ylmethyl-4-fluor-benzonitril zur behandlung von diabetes, krebs, autoimmunerkrankungen und hiv- infektionen |
JP2010504088A (ja) * | 2006-09-21 | 2010-02-12 | プロビオドルグ エージー | グルタミニルシクラーゼに関連した新規遺伝子 |
CN101573450B (zh) * | 2006-09-21 | 2015-12-16 | 前体生物药物股份公司 | 与谷氨酰环化酶相关的新基因 |
US8889709B2 (en) | 2006-09-21 | 2014-11-18 | Probiodrug Ag | Use of isoQC inhibitors in the treatment and prevention of inflammatory diseases or conditions |
US9277737B2 (en) | 2006-09-21 | 2016-03-08 | Probiodrug Ag | Mouse models carrying a knock-out mutation of the QPCTL-gene |
WO2008055945A1 (en) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
US8420684B2 (en) * | 2006-11-09 | 2013-04-16 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
US7741354B2 (en) * | 2006-11-09 | 2010-06-22 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
ATE554085T1 (de) | 2006-11-30 | 2012-05-15 | Probiodrug Ag | Neue inhibitoren von glutaminylcyclase |
KR100867978B1 (ko) * | 2006-12-12 | 2008-11-10 | 이화여자대학교 산학협력단 | 이중 작용기를 가지는 새로운 이온성 액체 및 그의제조방법 |
SI2121944T1 (sl) * | 2007-01-19 | 2011-12-30 | Probiodrug Ag | In vivo presejalni modeli za zdravljenje Alzheimerjeve bolezni in drugih motenj, povezanih s QPCT |
GB2447017A (en) * | 2007-03-01 | 2008-09-03 | Probiodrug Ag | New use for inhibitors of glutaminyl peptide cyclotransferinase |
EA201400366A1 (ru) * | 2007-03-01 | 2014-08-29 | Пробиодруг Аг | Новое применение ингибиторов глутаминилциклазы |
WO2008104580A1 (en) * | 2007-03-01 | 2008-09-04 | Probiodrug Ag | New use of glutaminyl cyclase inhibitors |
US7803810B2 (en) * | 2007-03-09 | 2010-09-28 | Probiodrug Ag | Inhibitors |
PE20090015A1 (es) * | 2007-03-13 | 2009-01-30 | Takeda Pharmaceutical | Preparacion solida |
US8093236B2 (en) * | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
US9034907B2 (en) | 2007-04-18 | 2015-05-19 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
EP2142513B1 (en) * | 2007-04-18 | 2014-03-12 | Probiodrug AG | Nitrovinyl-diamine derivatives as glutaminyl cyclase inhibitors |
JP5675342B2 (ja) * | 2007-04-18 | 2015-02-25 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのシアノグアニジン誘導体 |
EP2146968B1 (en) * | 2007-04-18 | 2015-09-23 | Probiodrug AG | Urea derivatives as glutaminyl cyclase inhibitors |
EP2865670B1 (en) | 2007-04-18 | 2017-01-11 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
US8202897B2 (en) * | 2007-04-18 | 2012-06-19 | Probiodrug Ag | Inhibitors of glutaminyl cyclases |
JP5676249B2 (ja) * | 2007-04-20 | 2015-02-25 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのアミノピリジン誘導体 |
US8524654B2 (en) * | 2007-05-21 | 2013-09-03 | The Uab Research Foundation | Prolyl endopeptidase inhibitors for reducing or preventing neutrophilic inflammation |
CA2696934A1 (en) * | 2007-09-12 | 2010-02-16 | Probiodrug Ag | Transgenic mice |
EP2238252B1 (en) * | 2008-01-14 | 2013-07-31 | Probiodrug AG | Mouse models carrying a knock-out mutation of the glutaminyl cyclase gene |
EP3047854B1 (en) | 2008-07-21 | 2018-03-21 | Probiodrug AG | Diagnostic antibody assay |
SG193148A1 (en) * | 2008-07-31 | 2013-09-30 | Probiodrug Ag | Glutaminyl cyclase as a diagnostic / prognostic indicator for neurodegenerative diseases |
US8962860B2 (en) * | 2008-09-04 | 2015-02-24 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
US20100144140A1 (en) * | 2008-12-10 | 2010-06-10 | Novellus Systems, Inc. | Methods for depositing tungsten films having low resistivity for gapfill applications |
NZ598685A (en) * | 2009-09-11 | 2013-05-31 | Probiodrug Ag | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
US20110152341A1 (en) | 2009-12-22 | 2011-06-23 | Probiodrug Ag | Cleavage of b-amyloid precursor protein |
WO2011101433A1 (en) | 2010-02-18 | 2011-08-25 | Probiodrug Ag | Methods of diagnosing inflammatory diseases by determining pyroglutamate-modified mcp-1 and screening methods for inhibitors of glutaminyl cyclase |
EP2542549B1 (en) | 2010-03-03 | 2016-05-11 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
US8269019B2 (en) | 2010-03-10 | 2012-09-18 | Probiodrug Ag | Inhibitors |
JP5945532B2 (ja) | 2010-04-21 | 2016-07-05 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体 |
WO2012022804A1 (en) | 2010-08-19 | 2012-02-23 | Probiodrug Ag | Crystal structure of glutaminyl cyclase |
RU2593759C2 (ru) * | 2010-09-03 | 2016-08-10 | ФОРМА ТиЭм, ЭлЭлСИ | Гуанидиновые соединения и композиции для ингибирования nampt |
EP2632466A4 (en) * | 2010-10-29 | 2014-03-19 | Univ Emory | QUINAZOLINE DERIVATIVES, COMPOSITIONS AND USES THEREOF |
KR101740042B1 (ko) | 2010-12-31 | 2017-05-25 | 애경산업(주) | 바이오필름 형성 억제 구강용 조성물 |
EP2686313B1 (en) | 2011-03-16 | 2016-02-03 | Probiodrug AG | Benzimidazole derivatives as inhibitors of glutaminyl cyclase |
KR102020072B1 (ko) | 2011-03-16 | 2019-11-04 | 프로비오드룩 아게 | 진단 항체 시험 |
CN103561776B (zh) * | 2011-05-27 | 2016-08-31 | 前体生物药物股份公司 | 放射性标记的谷氨酰胺酰环化酶抑制剂 |
JP6397407B2 (ja) | 2012-07-19 | 2018-09-26 | ドレクセル ユニバーシティ | 細胞タンパク質ホメオスタシスを調節するためのシグマ受容体リガンド |
JP2018501482A (ja) | 2014-12-19 | 2018-01-18 | プロビオドルグ エージー | pGlu−Abetaペプチドの検出のための新規の方法 |
DE102015011780A1 (de) | 2015-09-16 | 2017-03-16 | Hochschule Anhalt | Neue Glutaminylcyclase-lnhibitoren |
CN105384692B (zh) * | 2015-10-26 | 2018-06-29 | 深圳大学 | 一种谷氨酰胺酰基环化酶抑制剂 |
WO2019022600A1 (en) | 2017-07-24 | 2019-01-31 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | TREATMENT OF PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPA INTERACTION - CD47 |
EP3461819B1 (en) * | 2017-09-29 | 2020-05-27 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
US11117870B2 (en) | 2017-11-01 | 2021-09-14 | Drexel University | Compounds, compositions, and methods for treating diseases |
EP3521308B1 (en) | 2018-01-31 | 2024-03-13 | Vivoryon Therapeutics N.V. | Humanized and de-immunized antibodies |
CN109305942B (zh) * | 2018-08-23 | 2022-04-22 | 深圳大学 | 一种含有4-咪唑基的谷氨酰胺酰基环化酶抑制剂的制备方法及应用 |
CN108912051B (zh) * | 2018-08-23 | 2022-04-15 | 深圳大学 | 一种含有4-咪唑基的谷氨酰胺酰基环化酶抑制剂 |
WO2020113094A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
CN110950869B (zh) * | 2019-11-27 | 2022-07-15 | 深圳大学 | 一种作用于QC和GSK-3β的多靶向抑制剂的制备方法及其应用 |
CN110903292B (zh) * | 2019-11-27 | 2021-12-07 | 深圳大学 | 一种作用于QC和GSK-3β的多靶向抑制剂 |
CN114681447A (zh) * | 2020-12-30 | 2022-07-01 | 南京盛德瑞尔医药科技有限公司 | 一种戊酰胺类化合物作为谷氨酸脱氢酶抑制剂的应用 |
CN114681445A (zh) * | 2020-12-30 | 2022-07-01 | 南京盛德生物科技研究院有限公司 | 一种羧酰胺类化合物作为谷氨酸脱氢酶抑制剂的应用 |
WO2022268179A1 (en) * | 2021-06-24 | 2022-12-29 | Insilico Medicine Ip Limited | Beta-lactam derivatives for the treatment of diseases |
CN114874186B (zh) * | 2022-05-16 | 2023-07-11 | 深圳大学 | 一种谷氨酰胺酰基环化酶同工酶抑制剂及其制备方法与应用 |
CN114957127B (zh) * | 2022-05-24 | 2023-08-15 | 深圳大学 | 一种谷氨酰胺酰基环化酶抑制剂及其制备方法与应用 |
CN115317473B (zh) * | 2022-07-12 | 2023-10-13 | 中国人民解放军军事科学院军事医学研究院 | 棕榈酰化抑制剂在制备外周血造血干/祖细胞动员药物中的用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999007672A1 (en) * | 1997-08-05 | 1999-02-18 | Novo Nordisk A/S | Derivatives of 2,5- and 3,5-disubstituted anilines, their preparation and use |
WO2002016318A1 (en) * | 2000-08-21 | 2002-02-28 | Pacific Corporation | Novel thiourea derivatives and the pharmaceutical compositions containing the same |
Family Cites Families (261)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2961377A (en) | 1957-08-05 | 1960-11-22 | Us Vitamin Pharm Corp | Oral anti-diabetic compositions and methods |
US3174901A (en) | 1963-01-31 | 1965-03-23 | Jan Marcel Didier Aron Samuel | Process for the oral treatment of diabetes |
DE2009743A1 (de) | 1970-03-03 | 1971-09-16 | Farbenfabriken Bayer Ag, 5090 Leverkusen | Substituierte Biguanide mit antihyperglykämischer Wirkung |
US3879541A (en) | 1970-03-03 | 1975-04-22 | Bayer Ag | Antihyperglycemic methods and compositions |
US3960949A (en) | 1971-04-02 | 1976-06-01 | Schering Aktiengesellschaft | 1,2-Biguanides |
CH602612A5 (ko) | 1974-10-11 | 1978-07-31 | Hoffmann La Roche | |
JPS5731652A (en) * | 1980-07-29 | 1982-02-20 | Morishita Seiyaku Kk | Guanidine derivative |
JPS5736816A (ja) | 1980-08-14 | 1982-02-27 | Toshiba Corp | Chodendokoirunoseizohoho |
JPS605593B2 (ja) * | 1981-03-20 | 1985-02-12 | 北興化学工業株式会社 | イミダゾ−ル誘導体および農園芸用殺菌剤 |
JPS57192573A (en) | 1981-05-25 | 1982-11-26 | Hochiki Co | Fire fighting agent |
JPS58137075U (ja) | 1982-03-11 | 1983-09-14 | ダイワ精工株式会社 | 魚釣用両軸受型リ−ルのバツクラツシユ防止装置 |
US4568687A (en) * | 1983-02-28 | 1986-02-04 | American Cyanamid Company | N-[2-4-(1H-Imidazol-1-yl)alkyl]-arylamides and pharmaceutical compositions |
EP0117462A3 (en) | 1983-02-28 | 1986-08-20 | American Cyanamid Company | N-(2-4-(1h-imidazol-1-yl)alkyl)arylamides |
JPS60165712A (ja) | 1984-02-08 | 1985-08-28 | パイオニア株式会社 | 可変調整部品の自動調整方法 |
US4576957A (en) * | 1984-07-05 | 1986-03-18 | American Cyanamid Company | N-(Substituted phenyl)-N'-[(1H-imidazol-1-yl) and (1H-1,2,4-triazol-1-yl)alkyl]ureas |
JPS6126111A (ja) | 1984-07-16 | 1986-02-05 | Shin Meiwa Ind Co Ltd | 産業用ロボツト |
JPS6137764A (ja) | 1984-07-31 | 1986-02-22 | Suntory Ltd | 抗プロリルエンドペプチダ−ゼ活性を有する新規生理活性化合物 |
JPS6152021A (ja) | 1984-08-22 | 1986-03-14 | Fujitsu Ltd | スケルチ回路 |
JPS6172439A (ja) | 1984-09-18 | 1986-04-14 | Sanyo Electric Co Ltd | デ−タ転送方式 |
JPS6193566A (ja) | 1984-10-15 | 1986-05-12 | 株式会社 ジユピタ−電通 | フラツトケ−ブル用中継コネクタ |
EP0201743B1 (en) | 1985-04-16 | 1992-04-01 | Suntory Limited | Dipeptide derivatives of fatty acids, process for preparing them, pharmaceutical composition and use |
JPH0623190B2 (ja) | 1985-04-16 | 1994-03-30 | サントリー株式会社 | インヒビタ−活性を有するn−アシルピロリジン誘導体及びその製法並びに用途 |
US4873342A (en) | 1985-04-16 | 1989-10-10 | Suntory Limited | Dipeptide derivative and synthesis and use thereof |
JPS62114957A (ja) | 1985-11-13 | 1987-05-26 | Suntory Ltd | プロリルエンドペプチダ−ゼ阻害作用を有する新規ピロリジン誘導体およびその製法並びに用途 |
JPH0714878B2 (ja) | 1985-11-14 | 1995-02-22 | サントリー株式会社 | ピロリジンアミドを有効成分とするプロリルエンドペプチダーゼ阻害剤 |
JPH0764834B2 (ja) | 1985-11-29 | 1995-07-12 | サントリー株式会社 | プロリルエンドペプチダーゼ阻害活性を有する新規ピロリジンアミド誘導体およびその製法並びに用途 |
JPH0356486Y2 (ko) | 1986-01-27 | 1991-12-19 | ||
US5198458A (en) | 1986-02-04 | 1993-03-30 | Suntory Limited | Pyrrolidineamide derivatives of acylamino acid and pharmaceutical composition containing the same |
CA1320734C (en) | 1986-02-04 | 1993-07-27 | Suntory Limited | Pyrrolidineamide derivative of acylamino acid and pharmaceutical composition containing the same |
JPS6386485A (ja) | 1986-09-30 | 1988-04-16 | Agency Of Ind Science & Technol | トンネル型ジヨセフソン接合素子 |
JPH08806B2 (ja) | 1986-11-18 | 1996-01-10 | サントリー株式会社 | プロリルエンドペプチダ−ゼ阻害作用を有する新規ピロリジンアミド誘導体 |
US5254550A (en) | 1986-11-20 | 1993-10-19 | Ono Pharmaceutical Co., Ltd. | Prolinal derivatives and pharmaceutical compositions thereof |
DE3786229T2 (de) | 1986-11-20 | 1993-10-07 | Ono Pharmaceutical Co | Prolinalderivate. |
JPS63162672A (ja) | 1986-12-25 | 1988-07-06 | Ono Pharmaceut Co Ltd | 新規なプロリナ−ル誘導体、それらの製造方法およびそれらを含有する抗健忘症剤 |
JPH049367Y2 (ko) | 1986-12-27 | 1992-03-09 | ||
EP0275482B1 (en) | 1986-12-29 | 1993-01-20 | Ono Pharmaceutical Co., Ltd. | Proline derivatives |
US5262431A (en) | 1986-12-29 | 1993-11-16 | Ono Pharmaceutical Co., Ltd. | Prolinal derivatives and pharmaceutical compositions thereof |
JPH089591B2 (ja) | 1986-12-29 | 1996-01-31 | 小野薬品工業株式会社 | 新規なプロリナール誘導体 |
ES2054712T3 (es) | 1987-02-04 | 1994-08-16 | Ono Pharmaceutical Co | Un procedimiento para la preparacion de los derivados de prolinal. |
ES2103287T3 (es) | 1987-02-23 | 1997-09-16 | Ono Pharmaceutical Co | Nuevos derivados de tiazolidina. |
DE3712365A1 (de) | 1987-04-11 | 1988-10-27 | Hoechst Ag | Neue 2-acylpyrrolidin-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel sowie deren verwendung |
JPS6442465A (en) | 1987-08-07 | 1989-02-14 | Wakunaga Pharma Co Ltd | N-acylprolylpyrrolidine derivative, production and use thereof |
JP2649237B2 (ja) | 1988-03-07 | 1997-09-03 | キッセイ薬品工業 株式会社 | チアゾリジン誘導体 |
US4857524A (en) | 1987-08-08 | 1989-08-15 | Kissei Pharmaceutical Co., Ltd. | Thiazolidine compounds and therapeutic method |
JP2515558B2 (ja) | 1987-09-10 | 1996-07-10 | 株式会社ヤクルト本社 | 新規なペプチドおよびそれを有効成分とする抗健忘症剤 |
US4935493A (en) | 1987-10-06 | 1990-06-19 | E. I. Du Pont De Nemours And Company | Protease inhibitors |
JPH0543040Y2 (ko) | 1987-10-23 | 1993-10-28 | ||
JPH0742309B2 (ja) | 1987-11-30 | 1995-05-10 | キッセイ薬品工業株式会社 | チアゾリジン誘導体 |
JPH01250370A (ja) | 1987-12-23 | 1989-10-05 | Zeria Pharmaceut Co Ltd | 新規アミノ酸イミド誘導体、製法ならびに用途 |
JPH0647118Y2 (ja) | 1988-03-12 | 1994-11-30 | ワイケイケイアーキテクチュラルプロダクツ株式会社 | 門扉装置 |
US5053414A (en) | 1988-04-08 | 1991-10-01 | Ono Pharmaceutical Co., Ltd. | Heterocyclic compounds |
JPH0331298Y2 (ko) | 1988-05-19 | 1991-07-03 | ||
US5328899A (en) | 1988-07-15 | 1994-07-12 | The Salk Institute For Biological Studies | NPY peptide analogs |
ZA896376B (en) | 1988-08-26 | 1990-05-30 | Merrell Dow Pharma | Neuropeptide y agonists |
ZA896374B (en) | 1988-08-26 | 1990-05-30 | Merrell Dow Pharma | Neuropeptide y antagonists |
JP2531989B2 (ja) | 1988-09-14 | 1996-09-04 | 吉富製薬株式会社 | ピリジン化合物 |
CA2004028C (en) | 1988-12-08 | 1998-09-22 | Motoki Torizuka | Condensed benzene derivative |
US5433955A (en) | 1989-01-23 | 1995-07-18 | Akzo N.V. | Site specific in vivo activation of therapeutic drugs |
JPH02207070A (ja) | 1989-02-07 | 1990-08-16 | Zeria Pharmaceut Co Ltd | アミノ酸イミド誘導体、それを含有する医薬及び該化合物の製造中間体 |
JP2691442B2 (ja) | 1989-02-20 | 1997-12-17 | 株式会社ヤクルト本社 | 新規なプロリン誘導体 |
US5118811A (en) | 1989-04-13 | 1992-06-02 | Japan Tobacco Inc. | Amino acid derivatives possessing prolyl endopeptidase-inhibitory activities |
JPH0331298A (ja) | 1989-06-28 | 1991-02-12 | Ajinomoto Co Inc | プロリルエンドペプチターゼ阻害ペプチド |
JPH082869B2 (ja) | 1989-07-24 | 1996-01-17 | キッセイ薬品工業株式会社 | 健忘症治療剤およびプロリン誘導体 |
JPH0776211B2 (ja) | 1989-07-24 | 1995-08-16 | キッセイ薬品工業株式会社 | ピログルタミン酸誘導体 |
JPH07103101B2 (ja) | 1989-07-24 | 1995-11-08 | キッセイ薬品工業株式会社 | ピログルタミン酸誘導体 |
JPH082791B2 (ja) | 1989-07-24 | 1996-01-17 | キッセイ薬品工業株式会社 | 健忘症治療剤 |
JPH0633359Y2 (ja) | 1989-08-04 | 1994-08-31 | 石川島播磨重工業株式会社 | ガス冷却装置 |
JPH0356486U (ko) | 1989-10-06 | 1991-05-30 | ||
DE3939797A1 (de) | 1989-12-01 | 1991-06-06 | Basf Ag | Neue vom neuropeptid y abgeleitete peptide |
NL9000132A (nl) * | 1990-01-19 | 1991-08-16 | Cedona Pharm Bv | Nieuwe thiazoolderivaten. |
JPH04211648A (ja) | 1990-07-27 | 1992-08-03 | Nippon Kayaku Co Ltd | ケト酸アミド誘導体 |
JPH03255080A (ja) | 1990-03-05 | 1991-11-13 | Yoshitomi Pharmaceut Ind Ltd | ベンゼン化合物 |
US5073549A (en) | 1990-03-22 | 1991-12-17 | Bristol-Myers Squibb Company | BU-4164E - A and B, prolyl endopeptidase inhibitors and their methods of use |
US4999349A (en) | 1990-03-22 | 1991-03-12 | Bristol-Myers Squibb Co. | BU-4164E - A and B, prolyl endopeptidase inhibitors |
US5462928A (en) | 1990-04-14 | 1995-10-31 | New England Medical Center Hospitals, Inc. | Inhibitors of dipeptidyl-aminopeptidase type IV |
JPH049367A (ja) | 1990-04-26 | 1992-01-14 | Zeria Pharmaceut Co Ltd | アリールアルカノイル誘導体,該化合物の製造中間体及びそれらを含有する医薬 |
US5077409A (en) | 1990-05-04 | 1991-12-31 | American Cyanamid Company | Method of preparing bis-aryl amide and urea antagonists of platelet activating factor |
US6517824B1 (en) | 1990-05-14 | 2003-02-11 | University Of Medicine & Denistry Of New Jersey | Polymer compositions comprising antifibrotic agents, and methods of treatment, pharmaceutical compositions, and methods of preparation therefor |
JPH049367U (ko) | 1990-05-16 | 1992-01-28 | ||
WO1991018891A1 (en) | 1990-06-04 | 1991-12-12 | Pfizer Inc. | Aromatic pyrrolidine and thiazolidine amides |
EP0536399B1 (en) | 1990-06-07 | 1996-01-24 | Zeria Pharmaceutical Co., Ltd. | Novel arylalkanoylamine derivative and drug containing the same |
US5506256A (en) | 1990-07-27 | 1996-04-09 | Yoshitomi Pharmaceutical Industries, Ltd. | Proline derivatives possessing prolyl endopeptidase-inhibitory activity |
JPH05186498A (ja) | 1991-12-27 | 1993-07-27 | Japan Tobacco Inc | プロリン誘導体 |
EP0468469A2 (en) | 1990-07-27 | 1992-01-29 | Japan Tobacco Inc. | Proline derivatives |
JPH04235162A (ja) | 1990-08-09 | 1992-08-24 | Zeria Pharmaceut Co Ltd | 新規コハク酸アミド誘導体およびそれを含有する医薬 |
JPH04208299A (ja) | 1990-11-30 | 1992-07-29 | Ajinomoto Co Inc | プロリルエンドペプチターゼ阻害ペプチド |
DE4040300A1 (de) | 1990-12-17 | 1992-07-02 | Leifeld Gmbh & Co | Drueckmaschine mit wenigstens einem rollenhalter |
JPH04334357A (ja) | 1991-05-02 | 1992-11-20 | Fujirebio Inc | 酵素阻害作用を有するアシル誘導体 |
CA2089890A1 (en) | 1991-06-20 | 1992-12-21 | Makoto Yoshihama | Prolyl endopeptidase inhibitors sna-115 and sna-115t, production thereof, and strain which produces said inhibitors |
GB9115740D0 (en) | 1991-07-20 | 1991-09-04 | Smithkline Beecham Plc | Medicaments |
EP0672054A4 (en) | 1991-12-19 | 1996-02-07 | Garvan Inst Med Res | NEW MOLECULE INHIBITING THE BIOLOGICAL FUNCTION OF THE TYROSINE NEUROPEPTIDE. |
JPH05301826A (ja) | 1991-12-24 | 1993-11-16 | Snow Brand Milk Prod Co Ltd | プロリルエンドペプチダーゼ阻害剤 |
JPH05201970A (ja) | 1992-01-24 | 1993-08-10 | Japan Tobacco Inc | 新規プロリン誘導体 |
HUT71353A (en) | 1992-04-01 | 1995-11-28 | Univ Toledo | 4-[4'-piperidinyl or 3'pirrolidinyl] substituted imidazoles as h3-receptor antagonists and therapeutic uses thereof |
JP3318622B2 (ja) | 1992-05-27 | 2002-08-26 | 独立行政法人産業技術総合研究所 | プロリルエンドペプチダーゼ阻害剤 |
GB9213215D0 (en) | 1992-06-20 | 1992-08-05 | Wellcome Found | Peptides |
IL106998A0 (en) | 1992-09-17 | 1993-12-28 | Univ Florida | Brain-enhanced delivery of neuroactive peptides by sequential metabolism |
WO1994006765A1 (en) * | 1992-09-17 | 1994-03-31 | Nippon Soda Co., Ltd. | Nitrogenous heterocyclic compound, process for producing the same, and pest control agent |
JPH06116284A (ja) | 1992-10-02 | 1994-04-26 | Yamanouchi Pharmaceut Co Ltd | 新規ペプチド |
FR2696740B1 (fr) | 1992-10-13 | 1994-12-30 | Dospharma Sa | Dérivés prodrogués de la diméthylbiguanide et applications comme médicaments. |
US5536737A (en) | 1992-11-20 | 1996-07-16 | Japan Tobacco Inc. | Compound having prolyl endopeptidase inhibitory activity and pharmaceutical use thereof |
JPH06192298A (ja) | 1992-12-24 | 1994-07-12 | Mitsui Toatsu Chem Inc | 新規機能性ペプチド |
DE4326465A1 (de) | 1993-01-20 | 1995-02-09 | Thomae Gmbh Dr K | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
JPH06234693A (ja) | 1993-02-09 | 1994-08-23 | Snow Brand Milk Prod Co Ltd | 新規イソテトラセノン系物質及びその製造法 |
FR2701480B1 (fr) | 1993-02-15 | 1995-05-24 | Sanofi Elf | Composés à groupe sulfamoyle et amidino, leur procédé de préparation et les compositions pharmaceutiques les contenant. |
FR2703050B1 (fr) | 1993-03-24 | 1995-04-28 | Adir | Nouveaux dérivés bicycliques azotés, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
JPH11501281A (ja) | 1993-06-18 | 1999-02-02 | ユニバーシティ オブ シンシナティ | 神経ペプチドyアンタゴニスト及びアゴニスト |
WO1995001352A1 (fr) | 1993-06-30 | 1995-01-12 | Zeria Pharmaceutical Co., Ltd. | Derive de thiazolidine et medicament le contenant |
JPH0768933A (ja) * | 1993-06-30 | 1995-03-14 | Mitsubishi Paper Mills Ltd | 可逆性感熱記録材料 |
DE69428703T2 (de) | 1993-07-23 | 2002-05-29 | Zaidan Hojin Biseibutsu | Pyrrolidin derivate |
CA2177821C (en) | 1993-12-02 | 2000-03-28 | Norton P. Peet | Prolyl endopeptidase inhibitors |
IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
US5705483A (en) | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
EP0658569B2 (en) | 1993-12-17 | 2008-11-26 | Mitsubishi Pharma Corporation | Method for decoloring human serum albumin |
WO1995022327A1 (en) | 1994-02-22 | 1995-08-24 | Knoll Ag | Use of 1-(arylalkylaminoalkyl) imidazoles for treating neurological damage |
JPH07267988A (ja) | 1994-03-31 | 1995-10-17 | Yamanouchi Pharmaceut Co Ltd | 新規ペプチド |
US5543396A (en) | 1994-04-28 | 1996-08-06 | Georgia Tech Research Corp. | Proline phosphonate derivatives |
US5552426A (en) | 1994-04-29 | 1996-09-03 | Eli Lilly And Company | Methods for treating a physiological disorder associated with β-amyloid peptide |
US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
US5663192A (en) | 1994-10-20 | 1997-09-02 | Eli Lilly And Company | Heterocyclic neuropeptide Y receptor antagonists |
WO1996012489A1 (en) | 1994-10-20 | 1996-05-02 | Eli Lilly And Company | Bicyclic neuropeptide y receptor antagonists |
US6562862B1 (en) | 1994-10-20 | 2003-05-13 | Eli Lilly And Company | Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y |
GB9500601D0 (en) | 1995-01-12 | 1995-03-01 | Wellcome Found | Modified peptides |
US5614379A (en) | 1995-04-26 | 1997-03-25 | Eli Lilly And Company | Process for preparing anti-obesity protein |
US5552411A (en) | 1995-05-26 | 1996-09-03 | Warner-Lambert Company | Sulfonylquinolines as central nervous system and cardiovascular agents |
US6448282B1 (en) | 1995-05-30 | 2002-09-10 | Gliatech, Inc. | 1H-4(5)-substituted imidazole derivatives |
US5668151A (en) | 1995-06-07 | 1997-09-16 | Bristol-Myers Squibb Company | Dihydropyridine NPY antagonists: piperidine derivatives |
US5554621A (en) | 1995-06-07 | 1996-09-10 | Bristol-Myers Squibb Company | Dihydropyridine NPY antagonists: nitrogen heterocyclic derivatives |
IL117997A0 (en) | 1995-06-07 | 1996-10-31 | Pfizer | Neuropeptide Y1 specific ligands |
US5635503A (en) | 1995-06-07 | 1997-06-03 | Bristol-Myers Squibb Company | Dihydropyridine npy antagonists: piperazine derivatives |
JP3727383B2 (ja) | 1995-07-31 | 2005-12-14 | 月桂冠株式会社 | プロリルエンドペプチダーゼ阻害剤 |
TR199700334T1 (tr) | 1995-09-01 | 1997-08-21 | Lilly Co Eli | Indolil nöropeptid y reseptör antagonistleri. |
DE19544686A1 (de) | 1995-11-30 | 1997-06-05 | Thomae Gmbh Dr K | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
DE19544687A1 (de) | 1995-11-30 | 1997-06-05 | Thomae Gmbh Dr K | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
DE19544685A1 (de) | 1995-11-30 | 1997-06-05 | Thomae Gmbh Dr K | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
AU7692996A (en) | 1995-12-01 | 1997-06-27 | Ciba-Geigy Ag | Receptor antagonists |
AU7692896A (en) | 1995-12-01 | 1997-06-27 | Novartis Ag | Quinazolin-2,4-diazirines as NPY receptor antagonist |
WO1997020820A1 (en) | 1995-12-01 | 1997-06-12 | Novartis Ag | Heteroaryl compounds |
AU1328197A (en) | 1995-12-01 | 1997-06-19 | Synaptic Pharmaceutical Corporation | Aryl sulfonamide and sulfamide derivatives and uses thereof |
AU7692696A (en) | 1995-12-01 | 1997-06-27 | Novartis Ag | Heteroaryl derivatives |
JPH09157253A (ja) | 1995-12-12 | 1997-06-17 | Yamanouchi Pharmaceut Co Ltd | 新規アミノ酸誘導体 |
EP0871442A1 (en) | 1996-01-09 | 1998-10-21 | Eli Lilly And Company | Benzimidzolyl neuropeptide y receptor antagonists |
US5662723A (en) | 1996-03-22 | 1997-09-02 | Libbey Glass Inc. | Apparatus and method for forming a decorative pattern on glassware having an edge |
DE19616486C5 (de) | 1996-04-25 | 2016-06-30 | Royalty Pharma Collection Trust | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
WO1997043278A1 (en) | 1996-05-14 | 1997-11-20 | Novo Nordisk A/S | Somatostatin agonists and antagonists |
AU3295297A (en) | 1996-06-04 | 1998-01-05 | Synaptic Pharmaceutical Corporation | Methods of modifying feeding behavior, compounds useful in such methods, and dna encoding a hypothalamic atypical neuropeptide y/peptide yy receptor (y5) |
ATE230403T1 (de) | 1996-07-23 | 2003-01-15 | Neurogen Corp | Einige amido- und ammo- substituierte benzylaminderivate: eine neue klasse von neuropeptid y1 spezifische ligande |
ES2197354T3 (es) | 1996-07-23 | 2004-01-01 | Neurogen Corporation | Derivados de bencilamina sustituidos con amido y amino; una nueva clase de ligandos especificos del neuropeptido y1. |
CA2260982A1 (en) | 1996-07-23 | 1998-01-29 | Neurogen Corporation | Certain substituted benzylamine derivatives; a new class of neuropeptide-y1 specific ligands |
US6849733B1 (en) | 1996-08-23 | 2005-02-01 | Agouron Pharmaceuticals, Inc. | Neuropeptide-Y ligands |
US6006753A (en) | 1996-08-30 | 1999-12-28 | Eli Lilly And Company | Use of GLP-1 or analogs to abolish catabolic changes after surgery |
JP3880664B2 (ja) | 1996-09-04 | 2007-02-14 | 月桂冠株式会社 | プロリルエンドペプチダーゼ阻害ペプチド |
US5827898A (en) | 1996-10-07 | 1998-10-27 | Shaman Pharmaceuticals, Inc. | Use of bisphenolic compounds to treat type II diabetes |
AU4944297A (en) | 1996-10-08 | 1998-05-05 | Novartis Ag | Modulation of apoptosis |
FR2754709B1 (fr) | 1996-10-23 | 1999-03-05 | Sanofi Sa | Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition |
US6011155A (en) | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
US5955548A (en) * | 1997-05-07 | 1999-09-21 | Novo Nordisk A/S | Substituted 3, 3-diamino-2-propenenitriles, their preparation and use |
US6979686B1 (en) * | 2001-12-07 | 2005-12-27 | Pharmacia Corporation | Substituted pyrazoles as p38 kinase inhibitors |
JP3255080B2 (ja) | 1997-05-28 | 2002-02-12 | 日新電機株式会社 | ガス絶縁開閉装置 |
SE9703414D0 (sv) | 1997-09-23 | 1997-09-23 | Astra Ab | New compounds |
ES2297897T3 (es) * | 1997-10-21 | 2008-05-01 | Wyeth | Compuestos farmaceuticamente activos y metodos de uso. |
WO1999024035A1 (en) * | 1997-11-10 | 1999-05-20 | Bristol-Myers Squibb Company | Benzothiazole protein tyrosine kinase inhibitors |
JP2002501889A (ja) | 1998-02-02 | 2002-01-22 | トラスティーズ オブ タフツ カレッジ | グルコース代謝を調節する方法、およびそれに関連する試薬 |
US5994379A (en) | 1998-02-13 | 1999-11-30 | Merck Frosst Canada, Inc. | Bisaryl COX-2 inhibiting compounds, compositions and methods of use |
US6444662B1 (en) | 1998-02-13 | 2002-09-03 | Willmar Schwabe Gmbh & Co. | Stable hyperforin salts, method for producing same and their use in the treatment of alzheimer's disease |
AU3034299A (en) | 1998-03-09 | 1999-09-27 | Fondatech Benelux N.V. | Serine peptidase modulators |
DE19823831A1 (de) | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
US6329395B1 (en) * | 1998-06-08 | 2001-12-11 | Schering Corporation | Neuropeptide Y5 receptor antagonists |
DE69904595T2 (de) | 1998-06-12 | 2003-11-27 | Sod Conseils Rech Applic | Betacarbolinverbindungen |
DE19828114A1 (de) | 1998-06-24 | 2000-01-27 | Probiodrug Ges Fuer Arzneim | Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV |
DE19828113A1 (de) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
ATE251465T1 (de) | 1998-07-31 | 2003-10-15 | Novo Nordisk As | In-vitro stimulation von beta zellen vermehrung |
DE19834591A1 (de) | 1998-07-31 | 2000-02-03 | Probiodrug Ges Fuer Arzneim | Verfahren zur Steigerung des Blutglukosespiegels in Säugern |
JP4208299B2 (ja) | 1998-08-19 | 2009-01-14 | 東レ株式会社 | 金属板貼合わせ成形加工用ポリエステルフィルム |
WO2000030674A1 (en) | 1998-11-26 | 2000-06-02 | Ferring Bv | Neuropeptide y y4 agents in the treatment of reproductive disorders |
GB2389113B (en) | 1999-02-10 | 2004-02-04 | Elan Pharm Inc | B-secretase inhibitor |
US6211182B1 (en) | 1999-03-08 | 2001-04-03 | Schering Corporation | Imidazole compounds substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms |
US6121311A (en) | 1999-04-28 | 2000-09-19 | Japan Tobacco Inc. | Method for treating cocainism |
MXPA01011321A (es) | 1999-05-05 | 2003-08-01 | Johnson & Johnson | Neuropeptidos y ligandos de receptores 3a, 4, 5, 9b-tetrahidro-1h-benz(e)indol-2-il amino derivados utiles en el tratamiento de obesidad y otros trastornos. |
JP3148739B2 (ja) | 1999-05-19 | 2001-03-26 | ドーマー株式会社 | プロリルエンドペプチダーゼ阻害剤 |
US6107317A (en) | 1999-06-24 | 2000-08-22 | Novartis Ag | N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
US6110949A (en) | 1999-06-24 | 2000-08-29 | Novartis Ag | N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
US6172081B1 (en) | 1999-06-24 | 2001-01-09 | Novartis Ag | Tetrahydroisoquinoline 3-carboxamide derivatives |
JP2003535034A (ja) | 1999-11-12 | 2003-11-25 | ギルフォード ファーマシューティカルズ インコーポレイテッド | ジペプチジルペプチダーゼiv阻害剤並びにジペプチジルペプチダーゼiv阻害剤の製造及び使用法 |
GB9928330D0 (en) | 1999-11-30 | 2000-01-26 | Ferring Bv | Novel antidiabetic agents |
US6380398B2 (en) | 2000-01-04 | 2002-04-30 | Novo Nordisk A/S | Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
AU2001228309A1 (en) | 2000-01-24 | 2001-08-07 | Novo-Nordisk A/S | N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv |
US7064145B2 (en) | 2000-02-25 | 2006-06-20 | Novo Nordisk A/S | Inhibition of beta cell degeneration |
US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
IL151368A0 (en) | 2000-03-31 | 2003-04-10 | Probiodrug Ag | Use of a dipeptidyl peptidase iv enzyme activity effector for the production of pharmaceutical compositions |
US6605589B1 (en) | 2000-03-31 | 2003-08-12 | Parker Hughes Institute | Cathepsin inhibitors in cancer treatment |
GB0010188D0 (en) | 2000-04-26 | 2000-06-14 | Ferring Bv | Inhibitors of dipeptidyl peptidase IV |
GB0010183D0 (en) | 2000-04-26 | 2000-06-14 | Ferring Bv | Inhibitors of dipeptidyl peptidase IV |
US20040110743A1 (en) | 2000-05-19 | 2004-06-10 | Masaomi Miyamato | -Secretase inhibitors |
JP2004502690A (ja) | 2000-07-04 | 2004-01-29 | ノボ ノルディスク アクティーゼルスカブ | 酵素dpp−ivのインヒビターである複素環式化合物 |
AU2001269123A1 (en) | 2000-07-10 | 2002-01-21 | Bayer Aktiengesellschaft | Regulation of human dipeptidyl-peptidase iv-like enzyme |
HU227882B1 (hu) | 2000-08-10 | 2012-05-29 | Mitsubishi Tanabe Pharma Corp | Prolinszármazékok és gyógyszerként való alkalmazásuk |
EP1313470A4 (en) | 2000-08-17 | 2005-02-16 | Gliatech Inc | NEW ALICYCLIC IMIDAZOLE AS H 3 ACTIVE SUBSTANCES |
TWI243162B (en) | 2000-11-10 | 2005-11-11 | Taisho Pharmaceutical Co Ltd | Cyanopyrrolidine derivatives |
EP1354882A1 (en) | 2000-12-27 | 2003-10-22 | Kyowa Hakko Kogyo Co., Ltd. | Dipeptidyl peptidase iv inhibitor |
EP1233021A3 (en) | 2001-02-20 | 2002-11-20 | Pfizer Products Inc. | An inhibitor of Beta amyloid cleavage enzyme |
SE0100566D0 (sv) * | 2001-02-20 | 2001-02-20 | Astrazeneca Ab | Compounds |
CN100408579C (zh) | 2001-02-24 | 2008-08-06 | 贝林格尔英格海姆法玛两合公司 | 黄嘌呤衍生物,其制法及其作为药物组合物的用途 |
CA2441092A1 (en) | 2001-03-27 | 2002-10-03 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
US6573287B2 (en) | 2001-04-12 | 2003-06-03 | Bristo-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method |
US7053072B2 (en) | 2001-05-11 | 2006-05-30 | Medimmune Oncology, Inc. | Methods for the administration of amifostine and related compounds |
CN1247570C (zh) * | 2001-05-24 | 2006-03-29 | 利奥制药有限公司 | 新的吡啶基氰基胍化合物 |
CA2450475A1 (en) | 2001-06-20 | 2003-01-03 | Linda Brockunier | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
DE60224189T2 (de) | 2001-06-20 | 2008-12-11 | Merck & Co., Inc. | Dipeptidylpeptidase-hemmer zur behandlung von diabetes |
GB0115517D0 (en) | 2001-06-25 | 2001-08-15 | Ferring Bv | Novel antidiabetic agents |
US20030130199A1 (en) | 2001-06-27 | 2003-07-10 | Von Hoersten Stephan | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents |
DE10150203A1 (de) | 2001-10-12 | 2003-04-17 | Probiodrug Ag | Peptidylketone als Inhibitoren der DPIV |
AU2002316437A1 (en) | 2001-06-27 | 2003-03-03 | Smithkline Beecham Corporation | Pyrrolidines as dipeptidyl peptidase inhibitors |
DE10154689A1 (de) | 2001-11-09 | 2003-05-22 | Probiodrug Ag | Substituierte Aminoketonverbindungen |
ZA200300833B (en) | 2001-06-27 | 2004-02-10 | Probiodrug Ag | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents. |
PL367527A1 (en) | 2001-06-27 | 2005-02-21 | Smithkline Beecham Corporation | Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
JP4357293B2 (ja) | 2001-06-27 | 2009-11-04 | スミスクライン ビーチャム コーポレーション | ジペプチジルペプチダーゼ阻害剤としてのフルオロピロリジン類 |
JP2005502624A (ja) | 2001-07-03 | 2005-01-27 | ノボ ノルディスク アクティーゼルスカブ | 糖尿病を治療するための、dpp−ivを阻害するプリン誘導体 |
UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
US6948038B2 (en) * | 2001-07-24 | 2005-09-20 | Microsoft Corporation | System and method for backing up and restoring data |
EP1426366A4 (en) | 2001-09-14 | 2004-12-08 | Mitsubishi Pharma Corp | THIAZOLIDE DERIVATIVES AND THEIR MEDICAL USE |
AU2002331311A1 (en) | 2001-09-19 | 2003-04-01 | Novo Nordisk A/S | Heterocyclic compounds that are inhibitors of the enzyme dpp-iv |
GB0125446D0 (en) | 2001-10-23 | 2001-12-12 | Ferring Bv | Novel anti-diabetic agents |
GB0125445D0 (en) | 2001-10-23 | 2001-12-12 | Ferring Bv | Protease Inhibitors |
US6861440B2 (en) | 2001-10-26 | 2005-03-01 | Hoffmann-La Roche Inc. | DPP IV inhibitors |
US7727964B2 (en) | 2001-11-26 | 2010-06-01 | Trustees Of Tufts College | Peptidomimetic inhibitors of post-proline cleaving enzymes |
CH698246B1 (de) | 2001-12-20 | 2009-06-30 | Hoffmann La Roche | Test zur Identifizierung von Inhibitoren von Beta-Sekretasen. |
WO2003057144A2 (en) | 2001-12-26 | 2003-07-17 | Guilford Pharmaceuticals | Change inhibitors of dipeptidyl peptidase iv |
US6727261B2 (en) | 2001-12-27 | 2004-04-27 | Hoffman-La Roche Inc. | Pyrido[2,1-A]Isoquinoline derivatives |
US7910586B2 (en) | 2002-01-04 | 2011-03-22 | The Rockefeller University | Compositions and methods for prevention and treatment of amyloid-β peptide-related disorders |
WO2003057204A2 (en) | 2002-01-08 | 2003-07-17 | Nordic Bioscience A/S | Modulation of iamt (pimt or pcmt) in immune system |
AU2003216274A1 (en) * | 2002-02-11 | 2003-09-04 | Neurocrine Biosciences, Inc. | Pyrrole derivatives as ligands of melanocortin receptors |
MXPA04007743A (es) | 2002-02-13 | 2004-10-15 | Hoffmann La Roche | Nuevos derivados de piridina y quinolina. |
RU2293731C2 (ru) | 2002-02-13 | 2007-02-20 | Ф.Хоффманн-Ля Рош Аг | Производные пиридина и пиримидина, способы их получения (варианты), фармацевтическая композиция и применение |
AU2003219690A1 (en) | 2002-02-19 | 2003-09-09 | Pharmacia And Upjohn Company | Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease |
HUP0200849A2 (hu) | 2002-03-06 | 2004-08-30 | Sanofi-Synthelabo | N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra |
US6743864B2 (en) | 2002-03-12 | 2004-06-01 | Basell Poliolefine Italia S.P.A. | Polyolefin compositions having high tenacity |
WO2003095421A1 (en) * | 2002-05-09 | 2003-11-20 | Mimotopes Pty Ltd | Amino acid analogues |
CN101760663A (zh) | 2002-07-18 | 2010-06-30 | 本田技研工业株式会社 | 铜合金,制造铜合金的方法,复合铜材料和制造复合铜材料的方法 |
EP1402888A1 (en) * | 2002-09-18 | 2004-03-31 | Jerini AG | The use of substituted carbocyclic compounds as rotamases inhibitors |
WO2004039773A2 (en) | 2002-10-30 | 2004-05-13 | Nordic Bioscience A/S | Coumpounds modulating the activity of gapdh and/or iamt |
ATE440827T1 (de) * | 2002-12-04 | 2009-09-15 | Ore Pharmaceuticals Inc | Melanocortin-rezeptormodulatoren |
AU2003279492A1 (en) | 2002-12-11 | 2004-06-30 | Pharmacia & Upjohn Company Llc | Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds |
FR2848452B1 (fr) | 2002-12-12 | 2007-04-06 | Aventis Pharma Sa | Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer |
EP1608319A4 (en) * | 2003-04-03 | 2007-02-28 | Univ California | IMPROVED HEMMER FOR SOLUBLE EPOXY HYDROLASE |
WO2004089366A1 (en) | 2003-04-10 | 2004-10-21 | Pfizer Japan, Inc. | Bicyclic compounds as nr2b receptor antagonists |
EP1622870A2 (en) | 2003-05-05 | 2006-02-08 | Prosidion Ltd. | Glutaminyl based dp iv-inhibitors |
US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
DE602004026289D1 (de) | 2003-05-05 | 2010-05-12 | Probiodrug Ag | Glutaminylcyclase-hemmer |
US8338120B2 (en) | 2003-05-05 | 2012-12-25 | Probiodrug Ag | Method of treating inflammation with glutaminyl cyclase inhibitors |
KR20120035203A (ko) | 2003-05-05 | 2012-04-13 | 프로비오드룩 아게 | 글루타미닐 및 글루타메이트 사이클라제의 이펙터의 용도 |
AU2004237408C9 (en) | 2003-05-05 | 2010-04-15 | Probiodrug Ag | Medical use of inhibitors of glutaminyl and glutamate cyclases |
CN1867324A (zh) | 2003-10-15 | 2006-11-22 | 前体生物药物股份公司 | 谷氨酰胺酰基环化酶效应物和谷氨酸环化酶效应物的应用 |
EP2338490A3 (en) * | 2003-11-03 | 2012-06-06 | Probiodrug AG | Combinations useful for the treatment of neuronal disorders |
US20050171112A1 (en) | 2003-11-03 | 2005-08-04 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
US7667044B2 (en) | 2003-11-03 | 2010-02-23 | Probiodrug Ag | Compounds for the treatment of neurological disorders |
AU2005210004B2 (en) | 2004-02-05 | 2010-10-28 | Probiodrug Ag | Novel inhibitors of glutaminyl cyclase |
JP4211648B2 (ja) | 2004-03-22 | 2009-01-21 | 日本電気株式会社 | ソフトウェアインストール方法およびシステム |
JP4235162B2 (ja) | 2004-11-18 | 2009-03-11 | 日本電信電話株式会社 | 画像符号化装置,画像符号化方法,画像符号化プログラムおよびコンピュータ読み取り可能な記録媒体 |
GB0704100D0 (en) | 2006-03-17 | 2007-04-11 | Vodafone Plc | Improvements in an ehspa architecture |
-
2005
- 2005-02-04 AU AU2005210004A patent/AU2005210004B2/en not_active Ceased
- 2005-02-04 WO PCT/EP2005/001153 patent/WO2005075436A2/en active Search and Examination
- 2005-02-04 CN CN2005800042893A patent/CN1918131B/zh not_active Expired - Fee Related
- 2005-02-04 KR KR1020067017874A patent/KR101099206B1/ko active IP Right Grant
- 2005-02-04 US US11/051,760 patent/US7304086B2/en active Active
- 2005-02-04 BR BRPI0507485-1A patent/BRPI0507485A/pt active Search and Examination
- 2005-02-04 JP JP2006551809A patent/JP4996926B2/ja not_active Expired - Fee Related
- 2005-02-04 EP EP05707206A patent/EP1713780B1/en not_active Not-in-force
- 2005-02-04 CA CA2554809A patent/CA2554809C/en active Active
-
2007
- 2007-10-24 US US11/923,307 patent/US7897633B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999007672A1 (en) * | 1997-08-05 | 1999-02-18 | Novo Nordisk A/S | Derivatives of 2,5- and 3,5-disubstituted anilines, their preparation and use |
WO2002016318A1 (en) * | 2000-08-21 | 2002-02-28 | Pacific Corporation | Novel thiourea derivatives and the pharmaceutical compositions containing the same |
Also Published As
Publication number | Publication date |
---|---|
CN1918131B (zh) | 2011-05-04 |
AU2005210004A1 (en) | 2005-08-18 |
CA2554809C (en) | 2014-04-29 |
WO2005075436A3 (en) | 2005-12-08 |
JP2007520520A (ja) | 2007-07-26 |
KR20060125884A (ko) | 2006-12-06 |
US20050215573A1 (en) | 2005-09-29 |
US7897633B2 (en) | 2011-03-01 |
CA2554809A1 (en) | 2005-08-18 |
AU2005210004B2 (en) | 2010-10-28 |
EP1713780A2 (en) | 2006-10-25 |
US20090018087A1 (en) | 2009-01-15 |
JP4996926B2 (ja) | 2012-08-08 |
US7304086B2 (en) | 2007-12-04 |
BRPI0507485A (pt) | 2007-07-10 |
WO2005075436A2 (en) | 2005-08-18 |
EP1713780B1 (en) | 2012-01-18 |
CN1918131A (zh) | 2007-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101099206B1 (ko) | 신규한 글루타미닐 시클라제 저해제 | |
US7371871B2 (en) | Inhibitors of glutaminyl cyclase | |
US7732162B2 (en) | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases | |
JP5523107B2 (ja) | グルタミニルシクラーゼの新規阻害剤 | |
JP5599614B2 (ja) | グルタミニルシクラーゼの新規阻害剤 | |
KR101121882B1 (ko) | 글루타미닐 및 글루타메이트 사이클라제 이펙터의 용도 | |
JP5379692B2 (ja) | 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての3−ヒドロキシ−1,5−ジヒドロ−ピロール−2−オン誘導体 | |
JP5667440B2 (ja) | グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体 | |
JP5707327B2 (ja) | 新規の阻害剤 | |
JP2010509285A (ja) | グルタミニルシクラーゼの新規阻害剤 | |
JP6050264B2 (ja) | グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体 | |
CN101668525A (zh) | 谷氨酰胺酰环化酶抑制剂的新用途 | |
IL176765A (en) | Inhibitors of glutaminyl cyclase | |
NZ548596A (en) | Novel inhibitors of glutaminyl cyclase and their use in treating neuronal diseases | |
EVANS | Schilling et al.(43) Pub. Date: Sep. 29, 2005 | |
MXPA06008868A (en) | Novel inhibitors of glutaminyl cyclase | |
CENTER | Schilling et al.(43) Pub. Date: Nov. 11, 2004 | |
ES2348500T3 (es) | Uso medico de inhibidores de glutaminil y glutamato ciclasas para el tratamiento de la enfermedad de alzheimer y el sindrome de down. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
J201 | Request for trial against refusal decision | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20141219 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20151215 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20161219 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20171207 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20181210 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20191217 Year of fee payment: 9 |